Melanotan Side Effects: What the Research Shows
Nausea and Flushing: Dose-Dependent Observations
Nausea, facial flushing, fatigue, yawning, and stretching are the most consistently documented adverse events across Phase I trials — mechanistically attributable to central MC4R activation.
Phase I and crossover trial adverse events
dose-dependent / transient (Phase I)
melanotan side effects most consistently documented across Phase I trials and observational data are nausea, facial flushing, fatigue, yawning, and stretching. These were the most common adverse events in the 1996 Dorr Phase I study (dose escalation 0.01–0.03 mg/kg/day) and in the Wessells 1998 crossover trial (0.025 mg/kg).[3][5][6]
The nausea and autonomic side effects are mechanistically attributable to central MC4R activation: the Paiva 2017 rat study demonstrated that IV MT-II induced Fos expression in hypothalamic magnocellular neurons and increased oxytocin neuronal firing — the same pathway that mediates yawning, stretching, and nausea-adjacent autonomic responses.[26]
Nausea was generally dose-dependent and transient in Phase I. The 2021 qualitative study of 623 forum entries from 205 self-administered MT-II users confirmed nausea and facial flushing as the predominant adverse themes in unmonitored real-world use.[23] In uncontrolled populations, adverse effects may be compounded by unverified compound purity, incorrect doses, and combined sunbed use.
Renal Adverse Events in the Literature
Two published case reports document serious renal adverse events following MT-II use. Both involved doses substantially above the Phase I study range.
Case 1: Renal infarction — Peters et al. 2020
27 mg cumulative / 50% kidney infarcted
A 45-year-old male who self-administered 27 mg of MT-II subcutaneously over 6 months developed right-sided renal infarction affecting approximately 50% of the kidney. Laboratory findings: CRP 152 mg/L, elevated creatinine (102 µmol/L), hematuria, hypertension (165/95 mmHg). CT confirmed the infarction. Follow-up renal function: 81 mL/min per 1.73 m² (mildly reduced). Proposed mechanism: thrombotic pharmacological effects at cumulative high doses.[11]
Case 2: Rhabdomyolysis and AKI — Nelson & Bryant 2012
CPK 17,773 IU/L / ICU 3 days
A 39-year-old man injected 6 mg MT-II subcutaneously in a single dose (approximately 6x the Phase I starting dose). CPK peaked at 17,773 IU/L at 12 hours, confirming rhabdomyolysis; creatinine 2.25 mg/dL indicated acute kidney injury. ICU admission for 3 days required.[12]
Both cases involved doses substantially above the Phase I study range. Neither constitutes evidence from controlled research. They represent the documented renal risk profile from self-administered uncontrolled use.
Mole Changes and Melanocytic Nevi
Darkening and new appearance of melanocytic nevi documented in peer-reviewed case reports and regulatory safety notices (HPRA, TGA). Mechanism: increased MC1R stimulation in nevi-associated melanocytes.
Case 1: Dysplastic nevi — Hueso-Gabriel et al. 2012
severe dysplasia / JAAD publication
A 25-year-old man developed sudden eruption of multiple melanocytic nevi and rapid transformation of existing nevi after Melanotan use. Histopathology revealed dysplastic melanocytic nevi with severe dysplasia.[13] Published in Actas Dermosifiliogr (JAAD equivalent).
Case 2: FAMMM syndrome patient — Sivyer 2012
16-year-old / moderate atypia / partial reversal
A 16-year-old female with FAMMM syndrome who self-injected MT-II and attended UV tanning studios developed general skin tanning, multiple dark melanocytic nevi, and an enlarging nevus in the left groin. Histopathology: dysplastic compound nevus with moderate cytoarchitectural atypia. Three months after cessation, moles lightened and skin color paled.[14]
Mechanism: increased MC1R stimulation activates melanocytes in and around nevi — the same pathway driving skin pigmentation — potentially destabilizing existing nevi and stimulating new melanocyte proliferation. The FAMMM case demonstrates heightened risk in individuals with underlying genetic susceptibility, but the Hueso-Gabriel case occurred in a subject without reported baseline genetic risk.
Mucosal Melanoma and Oral Pigmentation
Mucosal malignant melanoma — Alsabbagh et al. 2025 (nasal spray)
22-year-old / anterior maxilla / IJOMS 2025
A 2025 case report documented a 22-year-old female who developed mucosal malignant melanoma of the anterior maxilla following use of unlicensed MT-II nasal spray for cosmetic tanning.[25] Published in the International Journal of Oral and Maxillofacial Surgery.
Oral mucosal pigmentation — Bonchev 2026
400 µg / 64 days / partial reversal at 3 mo
A 2026 case report documented oral mucosal pigmentation in a patient self-administering 400 µg every other day for 64 days cumulative (12.8 mg total). Gingival and buccal pigmentation developed and partially reversed after cessation; gingival pigmentation persisted with reduced intensity at 3 months.[24] MC1R is expressed in oral mucosal melanocytes — the same cascade driving skin pigmentation extends to this tissue.
Regulatory and Safety Context
Global regulatory status — FDA, TGA, HPRA, MHRA, WADA
UNAPPROVED / WADA S0
MT-I (afamelanotide/Scenesse) is EU/FDA-approved for erythropoietic protoporphyria with an established regulatory safety profile under prescription medical supervision. MT-II has no approved indication in any jurisdiction — not the US (FDA), the EU, Australia (TGA), Ireland (HPRA), or the UK (MHRA). WADA classifies MT-II under S0 (Non-Approved Substances) — prohibited in sport.
Human safety data is limited to small Phase I trials (3–20 subjects) conducted in the 1990s–2000s. The controlled Phase I data documented nausea as the predominant adverse event at 0.025 mg/kg. Serious adverse events in the published record derive entirely from case reports of self-administered, uncontrolled use at doses substantially above the Phase I range.
Melanotan II and Hormonal Effects
Testosterone and gonadotropic axis — Raposinho 2003
No effect on LH / GH axis (rat)
No controlled trial data on testosterone suppression or elevation by MT-II exists. A rodent study found that MT-II co-infusion with NPY cancelled NPY's orexigenic and adipogenic effects, but did not affect NPY-driven suppression of the gonadotropic axis (LH) or the somatotropic axis (GH).[22] MT-II's pro-erectile signaling operates via central MC4R activation — driving downstream NO-mediated responses in cavernosal tissue — not through gonadal androgen pathways. Testosterone was not a primary or secondary endpoint in any published MT-II human trial. There is no controlled evidence supporting either testosterone-raising or testosterone-suppressing effects.